A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
The Netherlands- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to the Netherlands48 clinical trials in Geleen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The Netherlands
The NetherlandsThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking trials exploring treatments for various cancer types, including gastric cancer, breast cancer, and lung cancer. Studies focus on innovative therapies and diagnostic approaches.
Multiple trials investigating personalized treatment approaches and immunotherapy options.
Comprehensive research into inflammatory bowel conditions, with particular focus on Crohn's Disease and Ulcerative Colitis. Studies evaluating long-term treatment effectiveness.
Emphasis on developing sustainable treatment options for chronic conditions.
Advanced research into Multiple Sclerosis treatment and management. Trials focusing on long-term safety and efficacy of innovative therapies.
Investigation of treatment effectiveness in various MS disease courses.
Tell us about your condition – we search every trial in Europe and connect you with the right site.